Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Netanel A Horowitz

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
British Journal of Haematology|September 15, 2025
Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigmMichal Nordkin, Nashwa Fadaos, Ronit Leiba, et al.
European Journal of Haematology|October 17, 2022
The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter studyLiat Shargian, Odelia Amit, Hanna Bernstine, et al.
Annals of Hematology|December 11, 2024
In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumabNashwa Fadaos, Yossi Ben Dor, Tehila Azoulay, et al.
Antibodies (Basel, Switzerland)|August 27, 2024
Knowledge of the Serological Response to the Third BNT162b2 Vaccination May Influence Compliance of Healthcare Workers to Booster DoseAvi Magid, Khetam Hussein, Halima Dabaja-Younis, et al.
Blood Advances|April 21, 2020
CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphomaMeir Shamay, Jennifer A Kanakry, John S W Low, et al.
Leukemia & Lymphoma|September 14, 2017
Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?Ohad S Bentur, Ronit Gurion, Anat Gafter-Gvili, et al.
Blood Advances|November 27, 2019
BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a studyTsila Zuckerman, Ron Ram, Luiza Akria, et al.
Cancer|August 12, 2023
A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphomaOsnat Bairey, Alisa Taliansky, Amir Glik, et al.
Cancer Research|March 18, 2010
Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogenKris A Steinbrecher, Netanel A Horowitz, Elizabeth A Blevins, et al.
Haematologica|July 29, 2021
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodiesRonit Gurion, Uri Rozovski, Gilad Itchaki, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
British Journal of Haematology|September 15, 2025
Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigmMichal Nordkin, Nashwa Fadaos, Ronit Leiba, et al.
European Journal of Haematology|October 17, 2022
The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter studyLiat Shargian, Odelia Amit, Hanna Bernstine, et al.
Annals of Hematology|December 11, 2024
In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumabNashwa Fadaos, Yossi Ben Dor, Tehila Azoulay, et al.
Antibodies (Basel, Switzerland)|August 27, 2024
Knowledge of the Serological Response to the Third BNT162b2 Vaccination May Influence Compliance of Healthcare Workers to Booster DoseAvi Magid, Khetam Hussein, Halima Dabaja-Younis, et al.
Blood Advances|April 21, 2020
CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphomaMeir Shamay, Jennifer A Kanakry, John S W Low, et al.
Leukemia & Lymphoma|September 14, 2017
Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?Ohad S Bentur, Ronit Gurion, Anat Gafter-Gvili, et al.
Blood Advances|November 27, 2019
BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a studyTsila Zuckerman, Ron Ram, Luiza Akria, et al.
Cancer|August 12, 2023
A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphomaOsnat Bairey, Alisa Taliansky, Amir Glik, et al.
Cancer Research|March 18, 2010
Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogenKris A Steinbrecher, Netanel A Horowitz, Elizabeth A Blevins, et al.
Haematologica|July 29, 2021
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodiesRonit Gurion, Uri Rozovski, Gilad Itchaki, et al.
Pageof 7